secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revance Therapeutics, Inc. (—)
CIK:        0001479290
Form:       8-K
Filed at:   2023-12-15T23:59:59+00:00
Accession:  0001479290-23-000114
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revance Therapeutics adopts amended bylaws aligning with SEC Rule 14a-19 on universal proxy
--------------------------------------------------------------------------------

- Aligns director nomination and proxy solicitation with Rule 14a-19, requiring 67% voting power solicitation evidence.
- Enhances disclosure requirements for nominating stockholders, nominees, and their associates and affiliates.
- Removes references to California law and updates electronic notice provisions per Delaware DGCL changes.
- Effective immediately as of December 12, 2023, following Board approval.
- Includes immaterial modifications, conforming edits, and removal of loan-to-officers provision.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479290/000147929023000114/0001479290-23-000114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479290/000147929023000114/rvnc-20231212.htm
  HTML page:      https://secwatch.observer/filing/0001479290-23-000114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer